HIV Clinical Insights: From Lab to Patient Care

HIV remains a significant public health concern worldwide, and diagnosis can be complicated. HIV presents with many of the same symptoms as other viral conditions, including COVID and the flu. Social (stigma), financial (cost), personal (fear) and system-wide (access) barriers exist for patients in need of testing. The time requirements to test for antibodies in the blood, and the layered nature of many current testing protocols influence the duration from exposure to diagnosis and treatment
 HIV Clinical Insights: From Lab to Patient Care

In a webinar presented at the Association for Diagnostics of Laboratory Medicine (ADLM 2025) conference, formerly AACC, John-Paul Bettencourt, DO, MPH, MBA, AAHIVS, CPE, HIV Specialist with the American Academy of HIV medicine, and Medical Director and Chief Medical Officer of The McGregor Clinic in Fort Myers, Fla., shared clinical insights from his experience in his clinical exam room.

HIV is complex

Dr. Bettencourt’s comprehensive overview covers the complexity of HIV and how it presents, the history and evolving trends in HIV testing, and the value of the clinician-lab relationship now and in the future.

Highlighted in the presentation is the important role of high-sensitivity immunoassays in the timely diagnosis and early initiation of treatment. Current HIV treatment is effective and powerful, but much depends upon early antiretroviral treatment.

Early treatment is key

Dr. Bettencourt drove home the point that early treatment is key with statistical data and a case study. With early treatment, one patient showed a 99.8% reduction in HIV viral load (from 52,400 to 141) 22 days after initiation of treatment. This type of response is important – not only because it improves outcomes for the patient, but also, early treatment is shown to dramatically reduce transmissions to monogamous partners and the community at large.

High-sensitivity immunoassays are vital

While modern HIV testing relies on advances in nucleic acid testing (NAT), HIV antigen/antibody combination tests and HIV-1/HIV-2 antibody differentiation tests, the future of HIV testing focuses greatly on sensitivity, both for in-clinic and in-home tests. Central to this are high-sensitivity 4th-generation immunoassays that can accurately detect the p24 antigen as quickly possible after exposure.

Dr. Lindsay Sun, M.D., M.S.
Dr. Lindsay Sun, M.D., M.S.
Dr. Sun joined Beckman Coulter in 2009 and has focused on bringing clinical insights into product development for Immunoassay projects, currently working on biomarkers in heart failure, blood virus, and Reproductive Endocrinology. Her expertise in statistics and knowledge of medical needs ensure the quality of research study design and analysis.

Related Articles

We are One: ADLM 2025 Clinical Lab Expo Highlights

We are One: ADLM 2025 Clinical Lab Expo Highlights

Immersed in the energy of Chicago, a dynamic ADLM 2025 brought together leading voices in clinical laboratory science, diagnostics innovation and disease management to exchange ideas and explore the future of patient care and scientific discovery. Held July 27-31, the conference set the stage for vibrant discussions about clinical AI integration, disease detection innovation, workflow optimization, and the growing impact of precision medicine on laboratory strategies and patient care.
The Value of Mean Platelet Volume (MPV) in Hematology

The Value of Mean Platelet Volume (MPV) in Hematology

Once thrombocytopenia is detected, it can be complex to identify the underlying cause. Learn how Mean Platelet Volume (MPV) delivers reliable, evidence-backed insight while supporting confident, efficient, and cost-conscious lab operations.
 HIV Clinical Insights: From Lab to Patient Care

HIV Clinical Insights: From Lab to Patient Care

HIV remains a significant public health concern worldwide, and diagnosis can be complicated. HIV presents with many of the same symptoms as other viral conditions, including COVID and the flu. Social (stigma), financial (cost), personal (fear) and system-wide (access) barriers exist for patients in need of testing. The time requirements to test for antibodies in the blood, and the layered nature of many current testing protocols influence the duration from exposure to diagnosis and treatment